These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 23295078)

  • 1. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
    Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a clinical practice guideline.
    Gupta AA; Yao X; Verma S; Mackay H; Hopkins L
    Curr Oncol; 2013 Oct; 20(5):e448-54. PubMed ID: 24155641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
    Hensley ML; Blessing JA; Degeest K; Abulafia O; Rose PG; Homesley HD
    Gynecol Oncol; 2008 Jun; 109(3):323-8. PubMed ID: 18394689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).
    Pautier P; Floquet A; Penel N; Piperno-Neumann S; Isambert N; Rey A; Bompas E; Cioffi A; Delcambre C; Cupissol D; Collin F; Blay JY; Jimenez M; Duffaud F
    Oncologist; 2012; 17(9):1213-20. PubMed ID: 22907974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
    Hensley ML; Miller A; O'Malley DM; Mannel RS; Behbakht K; Bakkum-Gamez JN; Michael H
    J Clin Oncol; 2015 Apr; 33(10):1180-5. PubMed ID: 25713428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature.
    Kanjeekal S; Chambers A; Fung MF; Verma S
    Gynecol Oncol; 2005 May; 97(2):624-37. PubMed ID: 15863170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.
    Hensley ML; Blessing JA; Mannel R; Rose PG
    Gynecol Oncol; 2008 Jun; 109(3):329-34. PubMed ID: 18534250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
    Hensley ML; Wathen JK; Maki RG; Araujo DM; Sutton G; Priebat DA; George S; Soslow RA; Baker LH
    Cancer; 2013 Apr; 119(8):1555-61. PubMed ID: 23335221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.
    Gadducci A; Grosso F; Scambia G; Raspagliesi F; Colombo N; Grignani G; Casali P; Sanfilippo R; Buonadonna A; Santoro A; Bruzzone M; Artioli G; Lorusso D; Biagioli E; Fossati R; Galli F; Negri E; Rulli E; Torri V; D'Incalci M
    Br J Cancer; 2018 Aug; 119(5):565-571. PubMed ID: 30057406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.
    Hensley ML; Ishill N; Soslow R; Larkin J; Abu-Rustum N; Sabbatini P; Konner J; Tew W; Spriggs D; Aghajanian CA
    Gynecol Oncol; 2009 Mar; 112(3):563-7. PubMed ID: 19135708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
    Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
    Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment for uterine leiomyosarcomas.
    Gadducci A; Guerrieri ME
    Expert Opin Pharmacother; 2015 Feb; 16(3):335-46. PubMed ID: 25418060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
    Takano T; Niikura H; Ito K; Nagase S; Utsunomiya H; Otsuki T; Toyoshima M; Tokunaga H; Kaiho-Sakuma M; Shiga N; Nagai T; Tanaka S; Otsuki A; Kurosawa H; Shigeta S; Tsuji K; Yamaguchi T; Yaegashi N
    Int J Clin Oncol; 2014 Oct; 19(5):897-905. PubMed ID: 24149774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
    Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
    Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy regimen for recurrent uterine leiomyosarcoma.
    Hu F; Ye Y; Begum H
    J Oncol Pharm Pract; 2024 Mar; 30(2):400-403. PubMed ID: 37787402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.
    Pautier P; Italiano A; Piperno-Neumann S; Chevreau C; Penel N; Firmin N; Boudou-Rouquette P; Bertucci F; Lebrun-Ly V; Ray-Coquard I; Kalbacher E; Bompas E; Collard O; Isambert N; Guillemet C; Rios M; Le Cesne A; Balleyguier C; Archambaud B; Duffaud F;
    N Engl J Med; 2024 Sep; 391(9):789-799. PubMed ID: 39231341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
    Littell RD; Tucker LY; Raine-Bennett T; Palen TE; Zaritsky E; Neugebauer R; Embry-Schubert J; Lentz SE
    Gynecol Oncol; 2017 Oct; 147(1):11-17. PubMed ID: 28747255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
    Hensley ML; Maki R; Venkatraman E; Geller G; Lovegren M; Aghajanian C; Sabbatini P; Tong W; Barakat R; Spriggs DR
    J Clin Oncol; 2002 Jun; 20(12):2824-31. PubMed ID: 12065559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy of systemic therapy for advanced uterine leiomyosarcoma: A systematic review, meta-analysis, and meta-regression analysis.
    Ijaz I; Shahzad MN; Hosseinifard H; Liu S; Sefidan MO; Kahloon LE; Imani S; Hua Z; Zhang YQ
    Cancer Med; 2023 Jul; 12(13):13894-13911. PubMed ID: 37081717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
    Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
    BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.